The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research Report: Human RASAL2 (UniProt Q9UJF2; RAS protein activator-like 2; nGAP)

0) Target verification (identity check)

The target in scope is human RASAL2 (RAS protein activator-like 2; also called nGAP) corresponding to UniProt Q9UJF2. Independent RasGAP-focused reviews describe RASAL2 as a PH–C2–RasGAP domain protein of ~1139 aa, consistent with the UniProt description and with RasGAP-family architecture. (stewart2020pumpingthebrakes pages 2-3)

1) Key concepts, definitions, and current understanding

1.1 Ras GTPase-activating proteins (RasGAPs) and the RAS “off reaction”

RAS proteins are small GTPases that toggle between an “on” (GTP-bound) and “off” (GDP-bound) state. RasGAPs accelerate the intrinsic GTP hydrolysis rate of RAS, thereby promoting the conversion of RAS-GTP → RAS-GDP (functional inactivation of RAS signaling). Reviews of Ras negative regulation highlight that the GTPase-stimulating activity resides in the C-terminal GAP domain and that loss of RasGAP function leads to accumulation of GTP-bound RAS with increased downstream signaling. (stewart2020pumpingthebrakes pages 2-3)

Primary molecular function (RASAL2): by definition and domain composition, RASAL2’s canonical biochemical role is to act as a RasGAP that down-regulates RAS signaling by accelerating GTP hydrolysis on RAS. (stewart2020pumpingthebrakes pages 2-3)

1.2 Domain architecture and how domains relate to function

A RasGAP review that explicitly lists RASAL2 describes it as a PH domain + C2 domain + C-terminal RasGAP domain protein. (stewart2020pumpingthebrakes pages 2-3)

Functional interpretation (current model): Ras is membrane-associated; therefore, noncatalytic domains (PH/C2) are widely discussed as contributing to membrane targeting and/or protein–protein interactions that position the GAP domain to engage membrane-localized RAS. (stewart2020pumpingthebrakes pages 2-3)

1.3 RASAL2 as a context-dependent signaling regulator in cancer

A RasGAP-centered cancer review synthesizes a major theme for RASAL2: it is frequently described as a tumor suppressor in multiple cancers (low expression associated with Ras–ERK activation and worse prognosis), yet it can also behave in some contexts as an oncogenic driver of EMT/metastasis, with reported links to YAP, Wnt/β-catenin, PI3K/AKT, and Rac1 pathway wiring. This is presented as a context-dependent phenomenon and a key interpretive issue in the RASAL2 literature. (bellazzo2020cuttingthebrakes pages 3-5)

2) Molecular function, pathways, and mechanistic roles

2.1 Pathway position: RAS–ERK/MAPK and PI3K/AKT

By its RasGAP catalytic function, RASAL2 is placed upstream of major RAS effector pathways (e.g., ERK/MAPK, PI3K/AKT) as a negative regulator. The “Ras brakes” reviews emphasize that RasGAP loss increases signaling through RAS-regulated pathways. (stewart2020pumpingthebrakes pages 2-3)

In luminal breast cancer models, combined perturbation of RasGAP tumor suppressors (RASAL2 with DAB2IP) is described as producing strong activation of ERK and AKT outputs, supporting the view that RasGAP co-loss can amplify multiple RAS-pathway branches. (olsen2017lossofrasgap pages 11-11)

2.2 Cooperation with DAB2IP: coupling RAS output and inflammatory/NF-κB signaling in ER+ breast cancer

A key mechanistic concept from the luminal breast cancer literature is cooperative tumor suppression by two RasGAPs, RASAL2 and DAB2IP. The Cancer Discovery study reports that combined loss promotes invasiveness and EMT, and that reconstitution of both genes suppresses metastasis in vivo. (olsen2017lossofrasgap pages 5-6, olsen2017lossofrasgap pages 7-8)

A later 2024 review focused on DAB2IP frames this cooperation as nonredundant and notes that concomitant loss of both RasGAPs “dramatically increased invasion and metastasis” in ER+ breast cancer models, reinforcing the concept that RasGAP network integrity is important for metastasis control. (fania2024anupdateon pages 1-2)

A 2024 JCI Insight paper also highlights that DAB2IP loss often occurs together with loss of RASAL2 and links this to poor outcome in luminal breast cancer contexts, placing RASAL2 within a clinically relevant RasGAP-loss state. (mukherjee2024dab2iplossin pages 1-2)

3) Subcellular localization (where RASAL2 acts)

RAS is anchored to membranes; accordingly, RasGAP modular domains are interpreted as contributing to localization. A Ras-regulator review explicitly lists RASAL2’s PH and C2 domains and discusses such domains as mediating membrane targeting and interactions enabling Ras engagement at membranes. (stewart2020pumpingthebrakes pages 2-3)

A RasGAP cancer review specifically notes phosphorylation within the PH domain and underscores that membrane localization is important for RasGAP function/activity. (bellazzo2020cuttingthebrakes pages 3-5)

Evidence limitation: The retrieved corpus contains general RasGAP-domain architecture and membrane-targeting interpretations (PH/C2), but limited direct, RASAL2-specific cell biology (e.g., imaging/localization maps) beyond these review statements; this should be considered when interpreting localization claims as inference from domain architecture rather than a definitive localization atlas. (stewart2020pumpingthebrakes pages 2-3, bellazzo2020cuttingthebrakes pages 3-5)

4) Regulation and post-translational modifications (PTMs)

4.1 AMPK-dependent phosphorylation and autophagy “switch” mechanism

A mechanistic Autophagy study (Feb 2021) reports a detailed regulatory model connecting RASAL2 to nutrient stress and autophagy:

• Under basal conditions, RASAL2 recruits PPM1B (pp2cβ), attenuating AMPK/PRKAA phosphorylation and suppressing basal autophagy. (bao2021prkaaampkαphosphorylationswitches pages 1-3, bao2021prkaaampkαphosphorylationswitches pages 3-4)
• Under glucose starvation, PPM1B dissociates and AMPK phosphorylates RASAL2 at S351, after which phosphorylated RASAL2 binds the PIK3C3/VPS34–ATG14–BECN1 (Beclin1) complex to increase PIK3C3 activity and autophagy. (bao2021prkaaampkαphosphorylationswitches pages 1-3, bao2021prkaaampkαphosphorylationswitches pages 3-4)

This work explicitly states that RASAL2 S351 phosphorylation functions as a molecular switch that can convert RASAL2 from an autophagy suppressor into an autophagy activator, and links this to breast tumor growth and poor outcomes (qualitatively described in the excerpt). (bao2021prkaaampkαphosphorylationswitches pages 1-3)

4.2 LKB1–AMPK-related kinase network and phosphorylation candidates

A phosphoproteomics-driven study of LKB1 signaling identifies RASAL2 as an LKB1-dependent phosphoprotein (>2-fold in both attached and detached datasets) and proposes candidate AMPK-related phosphorylation sites: S56, S89, S736, S864, S899. LKB1-dependent phosphorylation increases are reported at S89, S736, and S864, with genetic data implicating MARK kinases and SIK family members (notably SIK1+SIK3) in detachment-associated phosphorylation patterns; AMPK contributes partially in some assays. (kamireddy2020aquantitativephosphoproteomicsa pages 50-55, kamireddy2020aquantitativephosphoproteomicsa pages 55-59)

4.3 Additional reported phosphorylation in PH domain

A RasGAP cancer review notes that RASAL2 can be phosphorylated on Ser237 within the PH domain (review statement), consistent with the broader theme that regulatory phosphorylation can tune RasGAP localization or function. (bellazzo2020cuttingthebrakes pages 3-5)

5) Recent developments (prioritizing 2023–2024)

5.1 2023: RASAL2 as a tumor suppressor in cervical cancer

A 2023 study in cervical cancer (BIOCELL; Jan 2023) reports:

• RASAL2 is downregulated in cervical cancer tissues/cell lines; low expression correlates with advanced stage and metastasis. (chen2023rasal2actsas pages 1-2)
• In a cohort of 54 cervical cancer tissues (and 33 adjacent tissues), splitting patients into low (n=29) and high (n=25) RASAL2 groups, high RASAL2 expression is associated with reduced advanced clinical stage and metastasis (stage p=0.024, lymph node metastasis p=0.039, distant metastasis p=0.025) and improved survival (reported p<0.05). (chen2023rasal2actsas pages 3-7)

This study uses overexpression/knockdown in HeLa/SiHa cells to show functional suppression of proliferation/migration/invasion and induction of apoptosis with RASAL2 restoration. (chen2023rasal2actsas pages 3-7)

5.2 2024: Expert synthesis emphasizing cooperative RasGAP loss and therapeutic implications (via DAB2IP)

A 2024 review (Cell Death & Differentiation; Jun 2024) highlights that DAB2IP is a RasGAP and adaptor modulating multiple oncogenic pathways (NF-κB, Wnt/β-catenin, PI3K/AKT, MAPK) and explicitly notes functional cooperation with RASAL2 in limiting metastasis in ER+ breast cancer; the review frames restoration/upregulation of DAB2IP as a potential strategy that concurrently dampens multiple oncogenic pathways. (fania2024anupdateon pages 1-2, fania2024anupdateon pages 2-3)

A 2024 JCI Insight paper (Dec 2024) further contextualizes RasGAP loss as clinically meaningful in ER+ breast cancer, noting that DAB2IP loss often co-occurs with RASAL2 loss and that such RasGAP-loss states are associated with poorer outcomes, with an explicit statement that co-loss promotes poorer outcome in ~50% of Luminal B breast cancer. (mukherjee2024dab2iplossin pages 1-2)

6) Current applications and real-world implementations

6.1 Prognostic stratification / biomarker-style use (ER+ luminal breast cancer)

The strongest “real-world” implementation supported by the retrieved evidence is risk stratification based on RasGAP expression patterns.

In luminal B breast cancer, Olsen et al. (Cancer Discovery; Feb 2017) report tumor subsets with low RASAL2 and/or DAB2IP, including 16% low RASAL2, 24% low DAB2IP, and 22% low both. The combined low-expression state stratifies relapse-free survival with a highly significant log-rank P = 3.1×10⁻⁸. (olsen2017lossofrasgap pages 5-6, olsen2017lossofrasgap media 3a556391)

These quantitative patterns are visually supported by the paper’s figures: the low-expression distribution (pie chart) and Kaplan–Meier plot are available as extracted figure crops. (olsen2017lossofrasgap media 3a556391, olsen2017lossofrasgap media 8e13ab1a)

6.2 Preclinical mechanistic implementation: metastasis suppression circuitry

The same study provides preclinical “implementation” in the sense of actionable mechanistic circuitry: reconstitution of both RASAL2 and DAB2IP markedly reduced metastasis versus single-gene reconstitution controls in luminal breast cancer models (reported P values include P=0.043 vs RASAL2 alone, P=0.002 vs DAB2IP alone, and bioluminescence total flux P=0.004). (olsen2017lossofrasgap pages 7-8)

The authors also report clinical associations with stage: tumors lacking both genes were enriched for stage II–IV disease and differed from tumors expressing both genes (P<0.05), consistent with a metastasis/aggressiveness linkage. (olsen2017lossofrasgap pages 6-7)

6.3 Therapeutic targeting status

Using the clinical-trial search tool with “RASAL2” did not yield RASAL2-targeted interventional trials; the retrieved trial appears unrelated to RASAL2 biology, suggesting the term does not map cleanly to trial metadata in this interface. Therefore, current “applications” are better supported as biomarker/prognostic or mechanistic pathway uses rather than direct RASAL2-targeted therapeutics in clinical trials (based on available evidence). (mukherjee2024dab2iplossin pages 1-2)

7) Statistics and data highlights (recent and foundational)

• Luminal B breast cancer cohort (RASAL2/DAB2IP): 16% low RASAL2, 24% low DAB2IP, 22% low both; relapse-free survival separation log-rank P=3.1×10⁻⁸. (olsen2017lossofrasgap pages 5-6, olsen2017lossofrasgap media 3a556391)
• Luminal B stage association: tumors lacking both genes: 90% stage II–IV vs 10% stage I; tumors expressing both genes: 45% stage I (P<0.05). (olsen2017lossofrasgap pages 6-7)
• Metastasis suppression in vivo (reconstitution): dual RASAL2 + DAB2IP reconstitution reduces metastasis compared with single-gene reconstitution (P values reported above). (olsen2017lossofrasgap pages 7-8)
• Cervical cancer cohort (2023): n=54; high vs low RASAL2 correlates with clinical stage (p=0.024), lymph node metastasis (p=0.039), distant metastasis (p=0.025), and improved survival (p<0.05). (chen2023rasal2actsas pages 3-7)
• PTM candidates under LKB1 signaling: candidate phosphosites S56, S89, S736, S864, S899, with evidence for LKB1-dependent phosphorylation at S89/S736/S864 and involvement of MARK and SIK1+SIK3 in detachment-associated regulation. (kamireddy2020aquantitativephosphoproteomicsa pages 50-55, kamireddy2020aquantitativephosphoproteomicsa pages 55-59)

8) Expert opinions and analysis (authoritative synthesis)

A consistent expert synthesis across RasGAP-focused reviews is that Ras pathway hyperactivation can arise not only from RAS mutations but also from defects in RAS regulators, including RasGAP loss/inactivation; RasGAPs are modular proteins whose noncatalytic domains contribute to localization and regulatory interactions, meaning “RasGAP loss” can rewire signaling beyond simply increasing Ras-GTP. (stewart2020pumpingthebrakes pages 2-3, bellazzo2020cuttingthebrakes pages 3-5)

The 2024 DAB2IP review explicitly uses the RASAL2/DAB2IP cooperation as an example of nonredundant tumor-suppressive RasGAP circuitry in ER+ breast cancer metastasis and frames this as relevant to therapeutic thinking—particularly strategies that restore RasGAP function to dampen multiple oncogenic pathways simultaneously (in that review, emphasized for DAB2IP). (fania2024anupdateon pages 1-2)

9) Visual evidence from primary literature

Extracted figure regions from Olsen et al. (Cancer Discovery 2017) provide visual documentation of (i) the distribution of low RASAL2/DAB2IP expression states in luminal B tumors and (ii) the relapse-free survival stratification by combined RasGAP status, plus a schematic model for cooperative regulation of RAS and NF-κB signaling in metastasis. (olsen2017lossofrasgap media 3a556391, olsen2017lossofrasgap media 2deeb97b)

Summary table of key findings

Table: This table compiles the key evidence gathered for human RASAL2, covering molecular function, domains, localization, regulation, pathways, and disease relevance. It highlights residue-level PTMs, pathway interactions, and clinically relevant statistics from breast cancer studies.

10) Key gaps and recommended next steps (evidence-based limitations)

1. Direct localization evidence for RASAL2 (live-cell imaging showing plasma membrane/leading edge localization and dependence on PH/C2 domains) was not strongly represented in the retrieved full-text evidence; several statements are review-level or inferred from domain architecture and family behavior. Future targeted retrieval should prioritize RASAL2 imaging papers and domain-mutation localization assays. (stewart2020pumpingthebrakes pages 2-3, bellazzo2020cuttingthebrakes pages 3-5)
2. Several 2024 mechanistic studies flagged by search results (e.g., RASAL2 degradation in metastasis; renal fibrosis roles) were listed as unobtainable by the tool, limiting completeness for 2023–2024 mechanistic breadth. (mukherjee2024dab2iplossin pages 1-2)

References

1. (stewart2020pumpingthebrakes pages 2-3): Desmond R. Harrell Stewart and Geoffrey J. Clark. Pumping the brakes on ras – negative regulators and death effectors of ras. Journal of Cell Science, Feb 2020. URL: https://doi.org/10.1242/jcs.238865, doi:10.1242/jcs.238865. This article has 35 citations and is from a domain leading peer-reviewed journal.

2. (bellazzo2020cuttingthebrakes pages 3-5): Arianna Bellazzo and Licio Collavin. Cutting the brakes on ras—cytoplasmic gaps as targets of inactivation in cancer. Cancers, 12:3066, Oct 2020. URL: https://doi.org/10.3390/cancers12103066, doi:10.3390/cancers12103066. This article has 21 citations.

3. (olsen2017lossofrasgap pages 11-11): Sarah Naomi Olsen, Ania Wronski, Zafira Castaño, Benjamin Dake, Clare Malone, Thomas De Raedt, Miriam Enos, Yoko S. DeRose, Wenhui Zhou, Stephanie Guerra, Massimo Loda, Alana Welm, Ann H. Partridge, Sandra S. McAllister, Charlotte Kuperwasser, and Karen Cichowski. Loss of rasgap tumor suppressors underlies the aggressive nature of luminal b breast cancers. Cancer Discovery, 7(2):202-217, Feb 2017. URL: https://doi.org/10.1158/2159-8290.cd-16-0520, doi:10.1158/2159-8290.cd-16-0520. This article has 72 citations and is from a highest quality peer-reviewed journal.

4. (olsen2017lossofrasgap pages 5-6): Sarah Naomi Olsen, Ania Wronski, Zafira Castaño, Benjamin Dake, Clare Malone, Thomas De Raedt, Miriam Enos, Yoko S. DeRose, Wenhui Zhou, Stephanie Guerra, Massimo Loda, Alana Welm, Ann H. Partridge, Sandra S. McAllister, Charlotte Kuperwasser, and Karen Cichowski. Loss of rasgap tumor suppressors underlies the aggressive nature of luminal b breast cancers. Cancer Discovery, 7(2):202-217, Feb 2017. URL: https://doi.org/10.1158/2159-8290.cd-16-0520, doi:10.1158/2159-8290.cd-16-0520. This article has 72 citations and is from a highest quality peer-reviewed journal.

5. (olsen2017lossofrasgap pages 7-8): Sarah Naomi Olsen, Ania Wronski, Zafira Castaño, Benjamin Dake, Clare Malone, Thomas De Raedt, Miriam Enos, Yoko S. DeRose, Wenhui Zhou, Stephanie Guerra, Massimo Loda, Alana Welm, Ann H. Partridge, Sandra S. McAllister, Charlotte Kuperwasser, and Karen Cichowski. Loss of rasgap tumor suppressors underlies the aggressive nature of luminal b breast cancers. Cancer Discovery, 7(2):202-217, Feb 2017. URL: https://doi.org/10.1158/2159-8290.cd-16-0520, doi:10.1158/2159-8290.cd-16-0520. This article has 72 citations and is from a highest quality peer-reviewed journal.

6. (fania2024anupdateon pages 1-2): Rossella De Florian Fania, Arianna Bellazzo, and Licio Collavin. An update on the tumor-suppressive functions of the rasgap protein dab2ip with focus on therapeutic implications. Cell Death and Differentiation, 31:844-854, Jun 2024. URL: https://doi.org/10.1038/s41418-024-01332-3, doi:10.1038/s41418-024-01332-3. This article has 8 citations and is from a domain leading peer-reviewed journal.

7. (mukherjee2024dab2iplossin pages 1-2): Angana Mukherjee, Rasha T. Kakati, Sarah Van Alsten, Tyler Laws, Aaron L. Ebbs, Daniel P. Hollern, Philip M. Spanheimer, Katherine A. Hoadley, Melissa A. Troester, Jeremy M. Simon, and Albert S. Baldwin. Dab2ip loss in luminal a breast cancer leads to nf-κb–associated aggressive oncogenic phenotypes. Dec 2024. URL: https://doi.org/10.1172/jci.insight.171705, doi:10.1172/jci.insight.171705. This article has 4 citations and is from a domain leading peer-reviewed journal.

8. (bao2021prkaaampkαphosphorylationswitches pages 1-3): Yong Bao, Christopher Qian, Meng-Yue Liu, Fei Jiang, Xiaoxiao Jiang, Huijuan Liu, Zhuqing Zhang, Fanghui Sun, Ningwei Fu, Zhaoyuan Hou, Ya Ke, Yan Li, and Zhong-Ming Qian. Prkaa/ampkα phosphorylation switches the role of rasal2 from a suppressor to an activator of autophagy. Feb 2021. URL: https://doi.org/10.1080/15548627.2021.1886767, doi:10.1080/15548627.2021.1886767. This article has 22 citations and is from a domain leading peer-reviewed journal.

9. (bao2021prkaaampkαphosphorylationswitches pages 3-4): Yong Bao, Christopher Qian, Meng-Yue Liu, Fei Jiang, Xiaoxiao Jiang, Huijuan Liu, Zhuqing Zhang, Fanghui Sun, Ningwei Fu, Zhaoyuan Hou, Ya Ke, Yan Li, and Zhong-Ming Qian. Prkaa/ampkα phosphorylation switches the role of rasal2 from a suppressor to an activator of autophagy. Feb 2021. URL: https://doi.org/10.1080/15548627.2021.1886767, doi:10.1080/15548627.2021.1886767. This article has 22 citations and is from a domain leading peer-reviewed journal.

10. (kamireddy2020aquantitativephosphoproteomicsa pages 50-55): A Kamireddy. A quantitative phosphoproteomics screen to identify critical targets of the lkb1 tumor suppressor reveals gap proteins for ras superfamily gtpases as novel …. Unknown journal, 2020.

11. (kamireddy2020aquantitativephosphoproteomicsa pages 55-59): A Kamireddy. A quantitative phosphoproteomics screen to identify critical targets of the lkb1 tumor suppressor reveals gap proteins for ras superfamily gtpases as novel …. Unknown journal, 2020.

12. (chen2023rasal2actsas pages 1-2): LI CHEN, FANGFANG LI, SHOUYAN CAO, XIA LI, CHAO ZHOU, SAI HAN, and YOUZHONG ZHANG. Rasal2 acts as a tumor suppressor in cervical cancer cells. BIOCELL, 47:1549-1560, Jan 2023. URL: https://doi.org/10.32604/biocell.2023.027308, doi:10.32604/biocell.2023.027308. This article has 0 citations and is from a peer-reviewed journal.

13. (chen2023rasal2actsas pages 3-7): LI CHEN, FANGFANG LI, SHOUYAN CAO, XIA LI, CHAO ZHOU, SAI HAN, and YOUZHONG ZHANG. Rasal2 acts as a tumor suppressor in cervical cancer cells. BIOCELL, 47:1549-1560, Jan 2023. URL: https://doi.org/10.32604/biocell.2023.027308, doi:10.32604/biocell.2023.027308. This article has 0 citations and is from a peer-reviewed journal.

14. (fania2024anupdateon pages 2-3): Rossella De Florian Fania, Arianna Bellazzo, and Licio Collavin. An update on the tumor-suppressive functions of the rasgap protein dab2ip with focus on therapeutic implications. Cell Death and Differentiation, 31:844-854, Jun 2024. URL: https://doi.org/10.1038/s41418-024-01332-3, doi:10.1038/s41418-024-01332-3. This article has 8 citations and is from a domain leading peer-reviewed journal.

15. (olsen2017lossofrasgap media 3a556391): Sarah Naomi Olsen, Ania Wronski, Zafira Castaño, Benjamin Dake, Clare Malone, Thomas De Raedt, Miriam Enos, Yoko S. DeRose, Wenhui Zhou, Stephanie Guerra, Massimo Loda, Alana Welm, Ann H. Partridge, Sandra S. McAllister, Charlotte Kuperwasser, and Karen Cichowski. Loss of rasgap tumor suppressors underlies the aggressive nature of luminal b breast cancers. Cancer Discovery, 7(2):202-217, Feb 2017. URL: https://doi.org/10.1158/2159-8290.cd-16-0520, doi:10.1158/2159-8290.cd-16-0520. This article has 72 citations and is from a highest quality peer-reviewed journal.

16. (olsen2017lossofrasgap media 8e13ab1a): Sarah Naomi Olsen, Ania Wronski, Zafira Castaño, Benjamin Dake, Clare Malone, Thomas De Raedt, Miriam Enos, Yoko S. DeRose, Wenhui Zhou, Stephanie Guerra, Massimo Loda, Alana Welm, Ann H. Partridge, Sandra S. McAllister, Charlotte Kuperwasser, and Karen Cichowski. Loss of rasgap tumor suppressors underlies the aggressive nature of luminal b breast cancers. Cancer Discovery, 7(2):202-217, Feb 2017. URL: https://doi.org/10.1158/2159-8290.cd-16-0520, doi:10.1158/2159-8290.cd-16-0520. This article has 72 citations and is from a highest quality peer-reviewed journal.

17. (olsen2017lossofrasgap pages 6-7): Sarah Naomi Olsen, Ania Wronski, Zafira Castaño, Benjamin Dake, Clare Malone, Thomas De Raedt, Miriam Enos, Yoko S. DeRose, Wenhui Zhou, Stephanie Guerra, Massimo Loda, Alana Welm, Ann H. Partridge, Sandra S. McAllister, Charlotte Kuperwasser, and Karen Cichowski. Loss of rasgap tumor suppressors underlies the aggressive nature of luminal b breast cancers. Cancer Discovery, 7(2):202-217, Feb 2017. URL: https://doi.org/10.1158/2159-8290.cd-16-0520, doi:10.1158/2159-8290.cd-16-0520. This article has 72 citations and is from a highest quality peer-reviewed journal.

18. (olsen2017lossofrasgap media 2deeb97b): Sarah Naomi Olsen, Ania Wronski, Zafira Castaño, Benjamin Dake, Clare Malone, Thomas De Raedt, Miriam Enos, Yoko S. DeRose, Wenhui Zhou, Stephanie Guerra, Massimo Loda, Alana Welm, Ann H. Partridge, Sandra S. McAllister, Charlotte Kuperwasser, and Karen Cichowski. Loss of rasgap tumor suppressors underlies the aggressive nature of luminal b breast cancers. Cancer Discovery, 7(2):202-217, Feb 2017. URL: https://doi.org/10.1158/2159-8290.cd-16-0520, doi:10.1158/2159-8290.cd-16-0520. This article has 72 citations and is from a highest quality peer-reviewed journal.

19. (kamireddy2020aquantitativephosphoproteomics pages 50-55): A Kamireddy. A quantitative phosphoproteomics screen to identify critical targets of the lkb1 tumor suppressor reveals gap proteins for ras superfamily gtpases as novel …. Unknown journal, 2020.

20. (kamireddy2020aquantitativephosphoproteomics pages 55-59): A Kamireddy. A quantitative phosphoproteomics screen to identify critical targets of the lkb1 tumor suppressor reveals gap proteins for ras superfamily gtpases as novel …. Unknown journal, 2020.

Artifacts

• Edison artifact artifact-00
  

Citations

1. stewart2020pumpingthebrakes pages 2-3
2. bellazzo2020cuttingthebrakes pages 3-5
3. olsen2017lossofrasgap pages 11-11
4. fania2024anupdateon pages 1-2
5. olsen2017lossofrasgap pages 7-8
6. olsen2017lossofrasgap pages 6-7
7. olsen2017lossofrasgap pages 5-6
8. kamireddy2020aquantitativephosphoproteomicsa pages 50-55
9. kamireddy2020aquantitativephosphoproteomicsa pages 55-59
10. fania2024anupdateon pages 2-3
11. kamireddy2020aquantitativephosphoproteomics pages 50-55
12. kamireddy2020aquantitativephosphoproteomics pages 55-59
13. https://doi.org/10.1242/jcs.238865
14. https://doi.org/10.3390/cancers12103066
15. https://doi.org/10.1126/scisignal.2003669
16. https://doi.org/10.1080/15548627.2021.1886767
17. https://doi.org/10.1158/2159-8290.CD-16-0520
18. https://doi.org/10.1242/jcs.238865,
19. https://doi.org/10.3390/cancers12103066,
20. https://doi.org/10.1158/2159-8290.cd-16-0520,
21. https://doi.org/10.1038/s41418-024-01332-3,
22. https://doi.org/10.1172/jci.insight.171705,
23. https://doi.org/10.1080/15548627.2021.1886767,
24. https://doi.org/10.32604/biocell.2023.027308,

The search results contain extensive information about RASAL2, so I can confidently proceed with research on the correct gene.

Content Analysis from Search Results

Key sources to use:

Structural and Biochemical Function:
- [3], [14]: C2 domain augments RasGAP catalytic activity
- [12], [29]: RasGAP structures, mechanisms, regulation
- [25], [26], [51]: Membrane recruitment and lipid binding
- [1], [2], [4], [5]: Gene/protein annotation and domain structure

Localization:
- [11], [13], [16], [30]: Tissue expression and subcellular localization

Cancer-related Functions:
- [7], [8]: Tumor and metastasis suppressor in breast cancer
- [9], [22]: Stemness and EMT regulation
- [33], [40], [42]: Ovarian and colorectal cancer
- [37]: RAC1 activation and TNBC
- [38], [39], [45], [48]: Phosphorylation and autophagy regulation

Dual Specificity:
- [12], [20], [23]: Dual RasGAP/RapGAP activity
- [2]: Complementation assays

I'll explore additional regulatory mechanisms and protein interactions. The research reveals complex phosphorylation-dependent regulation, with AMPK playing a crucial role in modulating RASAL2's activity. Protein interaction studies highlight connections with the RASA1 family and potential cooperation with DAB2IP. These insights will help structure a comprehensive report that captures the multifaceted nature of RASAL2's molecular functions and significance.

Report Structure

I'll develop a systematic approach to presenting the research, focusing on molecular identity, biochemical mechanisms, and functional implications across different cellular contexts.

1. Highlight key findings on RASAL2's molecular characteristics
2. Analyze structural domains and catalytic mechanisms
3. Explore spatial regulation and substrate interactions
4. Investigate post-translational modifications
5. Examine tissue-specific functions and pathway regulations
6. Unpack context-dependent roles in cellular processes

The comprehensive analysis will provide a nuanced understanding of RASAL2's complex biological roles, particularly in cancer-related mechanisms.

RASAL2: Molecular Architecture, Regulation, and Context-Dependent Functions in Ras Signaling and Cancer Suppression

RASAL2 (RAS protein activator-like 2), also known as nGAP (neuronal GAP), is a dual-specificity GTPase-activating protein that catalyzes the hydrolysis of GTP-bound Ras and Rap small GTPases, converting them from their active GTP-bound state to their inactive GDP-bound state. The protein functions as a critical negative regulator of Ras signaling through a well-conserved catalytic mechanism while simultaneously exhibiting remarkable functional flexibility depending on cellular context, with roles ranging from tumor suppression in estrogen receptor-positive breast cancers to pro-tumorigenic functions in triple-negative breast cancer through calcium-regulated membrane recruitment and phosphorylation-dependent switches that alter its substrate specificity and binding interactions. This report synthesizes current knowledge regarding RASAL2's molecular mechanisms, structural architecture, regulatory mechanisms, tissue distribution, and context-dependent biological functions as revealed through biochemical, structural, cellular, and clinical studies spanning the past two decades.

Molecular Identity, Protein Architecture, and Gene Organization

RASAL2 is encoded by the RASAL2 gene located on chromosome 1 in humans (NC_000001.11)[1][5][32], with the protein consisting of 1,139 amino acids that organize into functionally distinct domains that together constitute a modular architecture characteristic of the RAS-GAP family[1][4][5]. The protein contains several essential structural elements including N-terminal pleckstrin homology (PH) domains, tandem calcium-binding C2 domains (C2A and C2B), and a catalytic GTPase-activating protein (GAP) domain at the carboxy terminus, with each domain contributing distinct regulatory or catalytic functions to the overall protein architecture[1][4][6][12]. The GAP-related domain (GRD) that characterizes this protein as a member of the GTPase-activating protein superfamily contains the catalytic machinery required to stabilize the transition state during GTP hydrolysis, facilitating the conversion of active Ras-GTP to inactive Ras-GDP at rates far exceeding the intrinsic GTPase activity of Ras alone[12][29]. RASAL2 is one of ten known mammalian RasGAPs, representing the broader GAP1 subfamily that includes related proteins such as RASAL1, CAPRI, and GAP1IP4BP, each characterized by the presence of multiple regulatory domains flanking the core catalytic GAP module[12][29][32].

The identification of RASAL2 sequences across diverse mammalian species, with approximately 96% conservation of Ras switch regulatory modules among mammalian orthologs[49], suggests ancient evolutionary origins and fundamental importance for Ras signaling regulation across vertebrates. Alternative splicing of the RASAL2 gene produces distinct transcript variants encoding different protein isoforms[4][32], a feature common to many RasGAP family members that may contribute to functional diversity in different cellular contexts. The protein atlas data indicate selective cytoplasmic and membranous expression patterns with particular abundance in neuronal cells and squamous epithelium[2][11][13][16][30], suggesting specialized roles in neuronal signaling and epithelial cell biology that warrant further investigation beyond the extensively studied cancer contexts.

Primary Biochemical Function: GTPase-Activating Activity and Catalytic Mechanism

RASAL2 functions biochemically as a GTPase-activating protein (GAP) that dramatically accelerates the hydrolysis of guanosine triphosphate (GTP) bound to small GTPases of the Ras family[1][7][12][29]. In the absence of RasGAP catalysis, Ras proteins exhibit an extremely slow intrinsic rate of GTP hydrolysis characterized by a half-life of approximately 15 minutes under physiological conditions, a kinetic limitation that would substantially impair cellular signal transduction if no regulatory mechanisms existed to accelerate this conversion[12]. RASAL2, through its catalytic GAP domain, increases the rate constant for K-Ras GTP hydrolysis by several orders of magnitude through a transition state stabilization mechanism that facilitates both the nucleophilic attack on the gamma-phosphate of GTP and the subsequent release of inorganic phosphate (Pi) from the Ras active site[12][29][56]. The catalytic strategy employed by RasGAPs involves insertion of a conserved arginine residue from the GAP domain into the nucleotide-binding pocket of Ras, a mechanism termed "arginine finger" catalysis, where this positively charged residue stabilizes the negative charge that develops on the gamma-phosphate during the transition state of the hydrolysis reaction[12][15][56].

The fundamental reaction catalyzed by RASAL2 can be conceptualized as conversion of the active signaling state (Ras-GTP) to the inactive signaling state (Ras-GDP), thereby terminating Ras-mediated cellular signaling cascades downstream of receptor tyrosine kinases and other activation mechanisms[7][12][29]. When RASAL2 activity is lost or suppressed through genetic, epigenetic, or post-translational modifications, elevated levels of Ras-GTP persist in cells, maintaining constitutive activation of downstream signaling pathways including the MAPK/ERK cascade and PI3K/Akt pathway, both critical for cell proliferation, survival, and transformation[7][9][40]. The catalytic domain alone exhibits measurably reduced activity compared to constructs containing both the C2 and GAP domains[3][14], a finding that prompted detailed structural investigation into how flanking domains contribute to full catalytic efficiency.

Structural Basis of Catalytic Activity: The Critical Role of the C2 Domain

Recent structural and biochemical investigations have revealed that the C2 domain immediately preceding the GAP catalytic domain plays an essential role in achieving full catalytic activity toward Ras substrates, a finding that fundamentally revised understanding of how RasGAP proteins achieve their catalytic capacity[3][14][58]. Through determination of the crystal structure of the C2-GAP region of RasGAP at 2.45 Ångstrom resolution, researchers demonstrated that the C2 domain directly contacts the allosteric lobe of Ras through a highly conserved surface centered around RasGAP residue R707, establishing an extensive protein-protein interface that augments catalytic efficiency[3][14][58]. This C2 domain interaction with Ras appears to facilitate inorganic phosphate (Pi) release following GTP hydrolysis, which represents the rate-limiting step in the overall catalytic cycle, meaning that the C2 domain effectively accelerates the slowest step in the GAP-catalyzed reaction rather than facilitating the initial nucleophilic attack itself[3][14]. Point mutation of R707 to cysteine (R707C) significantly impairs the catalytic advantage conferred by the C2 domain, with this same mutation naturally occurring in patients with vascular malformations, demonstrating disease relevance of the C2 domain-mediated catalytic mechanism[3][14][58].

AlphaFold structural predictions combined with sequence conservation analysis across GAP protein family members reveal that this C2 domain architectural feature is conserved across nine of the ten known RasGAPs, with nearly identical conserved surfaces across all GAP1m and SynGAP subfamily members[3][14][58]. In the case of SynGAP, mutation of the equivalent conserved C2 domain surface (corresponding to R707 in RasGAP) completely abrogates catalytic activity toward its preferred substrate Rap1, indicating that the structural and functional organization uncovered in RasGAP studies generalizes across a substantial fraction of mammalian RasGAP proteins[3][14]. In mice, introduction of the R707C mutation phenocopies vascular and signaling defects resulting from complete disruption of RASA1, the prototypical RasGAP family member, demonstrating that C2 domain integrity is essential not only for in vitro enzymatic activity but also for normal vascular development in vivo[3][14]. These findings establish the C2-GAP architecture as a conserved feature fundamental to RasGAP function across multiple protein family members.

Membrane Localization and Calcium-Dependent Recruitment

The catalytic activity of RASAL2 toward Ras substrates depends critically on subcellular localization, as the dual-specificity GAP proteins in the GAP1 subfamily show dramatically enhanced RasGAP activity upon translocation to biological membranes compared to their activity as soluble cytoplasmic proteins[25][26][51]. RASAL2, specifically recognized by its tandem C2 domains that function as calcium-responsive lipid-binding modules rather than as membrane-targeting calcium sensors per se, exhibits calcium-dependent association with the plasma membrane where both RASAL2 and its Ras substrates are concentrated[25][26][51]. The C2A domain of RASAL2 binds specifically to phosphatidylserine (PS), a major phospholipid constituent of cell membranes, while the C2B domain exhibits broader specificity for multiple phosphatidylinositol phosphates (PIPs) including phosphatidylinositol 3-phosphate (PI3P) and other inositol-containing lipids[25][26][51]. Colocalization of RASAL2 with Ras at membrane compartments represents a necessary but not sufficient condition for maximal RasGAP activation, as direct lipid binding through the C2 domains provides essential additional activation through mechanisms involving spatial organization, membrane curvature sensing, and conformational regulation[25][26][51].

The C2 domains of RASAL2, exhibiting high sequence homology to C2 domains in synaptotagmin proteins, possess hydrophobic residues (V22, V78, L149, and V206) at their tips that enable insertion into lipid bilayers and sensing or inducing of membrane curvature[25][26]. This ability to sense and promote membrane bending by insertion of hydrophobic loops into membrane structures represents a unique feature among GAP proteins that may connect RASAL2 function to broader cellular processes involving membrane deformation, such as endocytosis and exocytosis[25][26]. Studies using size-fractionated liposomes of varying curvature demonstrate that RASAL2 preferentially binds curved membrane structures, a preference that can be partially or completely abolished by mutation of the conserved hydrophobic residues, indicating functional importance of this membrane curvature-sensing capability[25][26]. The dissociation constant for RASAL2 binding to phosphatidylserine-containing vesicles or phosphatidylinositol 3-phosphate-enriched membranes ranges from approximately 30-35 μM, values consistent with other calcium-binding C2 domain proteins and suggesting moderate but specific lipid-binding interactions that can be modulated by intracellular calcium concentrations[25][26].

Dual Substrate Specificity: Ras and Rap GTPases

Although RASAL2 is primarily characterized and named for its GAP activity toward Ras proteins, biochemical evidence establishes that this protein functions as a dual-specificity GAP, capable of stimulating GTP hydrolysis of both Ras and Rap small GTPases, albeit with important differences in the substrate specificity depending on the cellular compartment and protein associations[12][20][23][26]. The isolated GAP domain of RASAL2 shows relatively poor catalytic activity toward Ras in solution but retains more substantial activity toward Rap, a substrate specificity profile that reverses dramatically upon membrane association through C2 domain-mediated lipid binding[26]. This substrate specificity switch represents a unique feature of dual-specificity GAPs in the GAP1 subfamily, where spatial recruitment to membranes and conformational regulation by C2 domains essentially convert the catalytic specificity from predominantly RapGAP activity to predominantly RasGAP activity[20][26]. The structural basis for this specificity switch involves different catalytic mechanisms between RasGAPs and RapGAPs, as RasGAPs provide a conserved arginine "finger" as the catalytic residue for Ras hydrolysis, while RapGAPs employ an asparagine "thumb" as the catalytic residue, utilizing different active site chemistry to accelerate the intrinsic GTPase activity of their respective substrates[12][20].

Cross-linking and mutation studies indicate that Ras and Rap proteins, despite their close structural similarity and comparable nucleotide-binding pocket architecture, interact with RASAL2 through distinct mechanisms that depend on nucleotide state and GAP domain orientation[12][20]. Genetic evidence from model organisms and cell-based studies suggests that the dual substrate specificity of RASAL2 and related proteins may provide redundancy in Ras pathway regulation while simultaneously allowing selective regulation of Rap-mediated signaling in particular cellular compartments or developmental contexts[20]. The C2 domain-mediated conformational activation that enhances RasGAP activity may preferentially orient the GAP domain toward Ras substrates while simultaneously restricting access of Rap proteins, representing a spatial and conformational basis for the substrate specificity switch observed upon membrane association[25][26].

Post-Translational Modifications and Phosphorylation-Dependent Functional Switches

RASAL2 function is dynamically regulated through phosphorylation at multiple sites, with post-translational modifications fundamentally altering the protein's substrate specificity, subcellular localization, interaction partners, and biological outcomes in ways that cannot be predicted from the primary amino acid sequence alone[8][18][36][38][39][45][48]. Phosphorylation of RASAL2 at serine 237 (S237) within the pleckstrin homology (PH) domain by AMPK (AMP-activated protein kinase) represents one of the best-characterized post-translational modifications, with this phosphorylation occurring in response to metabolic stress and glucose deprivation and promoting tumor growth in both estrogen receptor-positive and estrogen receptor-negative breast cancer cells[8][18][36][38][39][45][48]. In estrogen receptor-positive breast cancer cells, phosphorylated RASAL2 (p-Rasal2) expression levels are substantially lower than in estrogen receptor-negative cells, contributing to a differential balance of phosphorylated versus non-phosphorylated RASAL2 that appears to determine the functional outcome of total RASAL2 expression in different breast cancer subtypes[8][36][39].

Mechanistically, phosphorylation at S237 promotes secretion of RASAL2 into exosomes, small extracellular vesicles that mediate intercellular communication, with cancer cells taking up these phosphorylated-RASAL2-containing exosomes showing enhanced proliferation, migration, invasion, and metastatic capacity[8][36][39]. Another characterized phosphorylation site at serine 351 (S351) within the PH domain represents a target of AMPK-mediated phosphorylation under glucose-deprivation conditions, with this phosphorylation switching RASAL2 from a suppressor of autophagy under nutrient-rich conditions to a promoter of autophagy under nutrient-stress conditions[38][45][48]. Under nutrient-rich conditions, unphosphorylated RASAL2 associates with the phosphatase PPM1B to suppress AMPK phosphorylation and downstream autophagy initiation, while glucose starvation induces dissociation of PPM1B from RASAL2 and subsequent phosphorylation of RASAL2 at S351 by activated AMPK, leading to binding with the PIK3C3 (VPS34) autophagy initiation complex and promotion of autophagosome formation[38][45][48]. This phosphorylation-dependent switching of RASAL2 function from inhibitor to promoter of autophagy under different metabolic conditions represents an elegant example of how post-translational modifications can invert the functional role of a signaling protein.

Tissue Distribution and Subcellular Localization

RASAL2 exhibits selective expression patterns across human tissues, with highest expression levels detected in the central and peripheral nervous systems, consistent with the protein's alternative designation as neuronal GAP (nGAP), and substantial expression in epithelial tissues including squamous epithelium of the esophagus and vagina[2][11][13][16][30][32]. Immunohistochemical and protein atlas analyses reveal that RASAL2 localizes predominantly to the cytoplasm with enrichment at specific subcellular compartments including the plasma membrane and focal adhesion sites[2][11][13][30][32]. The focal adhesion localization is particularly notable given the known role of Ras signaling in integrin-mediated cell adhesion and migration, suggesting specialized functions for RASAL2 in regulating Ras activity at sites of cell-matrix contact[2][11][30][32]. Within the brain, RASAL2 shows particularly high expression in the hippocampal formation, amygdala, basal ganglia, and other regions involved in learning, memory, and emotional processing, suggesting roles in neuronal signaling beyond tumor suppression[2][13][16][30].

In cancer tissues, RASAL2 expression is typically downregulated in luminal B breast cancers, estrogen receptor-positive tumors, ovarian cancers, and colorectal cancers compared to adjacent normal tissues or normal epithelial cells[7][9][22][31][33][40][42], a finding with important prognostic implications as low RASAL2 levels associate with disease recurrence, metastatic progression, and poor overall survival in these tumor types[7][31]. Conversely, RASAL2 is frequently upregulated in triple-negative breast cancers and estrogen receptor-negative tumors, where its high expression predicts poor disease outcomes through distinct mechanisms involving RAC1 activation rather than Ras inhibition[37][39]. This context-dependent expression pattern, wherein RASAL2 appears suppressed in some cancer types while simultaneously upregulated in others, underscores the fundamental importance of cellular context in determining whether a given protein functions as a tumor suppressor or oncogenic driver.

Biological Functions in RAS Pathway Regulation and Cancer Suppression

RASAL2 functions as a negative regulator of the RAS-MAPK signaling pathway by catalyzing GTP hydrolysis of Ras proteins, thereby preventing accumulation of active Ras-GTP that drives proliferation, survival, and transformation signals[7][9][22][31][40][42]. Loss or suppression of RASAL2 in human breast cancers and other tumor types results in elevated levels of active Ras-GTP and consequent hyperactivation of downstream MAPK/ERK signaling, leading to increased phosphorylation of ERK and enhanced phosphorylation of transcription factors that drive cell proliferation[7][9][22][31][40]. In human breast cancer patient samples, RASAL2 loss or downregulation is observed in at least 20% of tumors, with the lowest RASAL2 expression particularly enriched in luminal B breast cancers where low RASAL2 levels correlate with tumor recurrence and poor overall survival[7][31]. Reconstitution of RASAL2 expression in breast cancer cells with low endogenous RASAL2 suppresses Ras-GTP levels, reduces phosphorylated ERK, and inhibits mammary tumor growth in xenograft models, providing functional confirmation that RASAL2 loss causally contributes to tumor phenotypes rather than simply correlating with them[7][31].

RASAL2 suppresses epithelial-mesenchymal transition (EMT), a cellular reprogramming process wherein epithelial cells acquire migratory and invasive properties characteristic of mesenchymal cells, through regulation of Ras-MAPK signaling and downstream transcription factors[7][9][22][33][40][42]. RASAL2 knockdown in bladder cancer cells promotes upregulation of mesenchymal markers including vimentin and N-cadherin while simultaneously suppressing epithelial markers such as E-cadherin, effects that are reversed by MEK/ERK pathway inhibition or SOX2 knockdown, establishing the Ras-MAPK-SOX2 axis as a critical downstream mediator of RASAL2-suppressive effects on EMT[9][22]. In ovarian cancer cells, RASAL2 depletion promotes anchorage-independent growth, cell migration, and invasion through enhanced EMT, with these effects accompanied by increased expression of EMT-promoting transcription factors Snail and Slug while epithelial adhesion molecules are suppressed[33][42]. The capacity of RASAL2 to inhibit cancer cell stemness, evidenced by reduced tumorsphere formation and decreased CD44+ cell populations in RASAL2-reconstituted cells, suggests additional roles beyond simple Ras pathway inhibition that may involve signaling through related small GTPases or non-catalytic protein-protein interactions[9][22].

Genetic studies in engineered mouse models provide in vivo validation of RASAL2's tumor-suppressive function, as Rasal2 mutations in luminal mammary cancer models (MMTV-neu transgenic mice) dramatically enhance metastasis, with the primary tumor that spontaneously lost or suppressed Rasal2 expression exhibiting the most robust Ras pathway activation and metastatic phenotype within the cohort[7][31]. Cooperation of Rasal2 loss with p53 mutations in mouse models promotes development and metastasis of multiple tumor types including mammary, lymphoid, and other cancers, suggesting that RASAL2 loss provides particular selective advantage when combined with loss of p53-mediated tumor suppression[7][31]. In a xenograft metastasis model utilizing human breast cancer cells, RASAL2 ablation promotes tumor growth and progression while RASAL2 reconstitution suppresses growth, and notably, RASAL2 ablation enhances spontaneous lung metastasis in tail-vein injection models, establishing RASAL2 suppression as a driver of the invasive and metastatic phenotype[7][31].

Context-Dependent Oncogenic Functions in Triple-Negative Breast Cancer

In striking contrast to its well-established tumor-suppressive role in luminal B estrogen receptor-positive breast cancers, RASAL2 exhibits an oncogenic function in triple-negative breast cancer (TNBC), a clinically aggressive subtype characterized by absence of estrogen, progesterone, and HER2 receptors[37][39]. RASAL2 expression is upregulated in TNBC and estrogen receptor-negative breast tumors compared to normal tissue and luminal tumors, with high RASAL2 expression predicting poor overall survival and increased metastasis and relapse within five years in patients with basal/TNBC tumors, displaying an inverse correlation with RASAL2 expression in luminal tumors[37][39]. The oncogenic functions of RASAL2 in TNBC operate independently of its canonical RAS-GAP catalytic activity, as demonstrated through studies showing that RASAL2 RAS-GAP catalytic domain mutants (K417A and K567A) retain full ability to promote invasion, whereas a GAP domain-deleted mutant loses this function, indicating that RASAL2 requires the GAP domain structure but not its catalytic activity toward Ras for TNBC promotion[37][39].

Mechanistically, RASAL2 promotes TNBC progression through activation of the small GTPase RAC1 via binding and antagonization of ARHGAP24, a GAP protein specific for RAC1, thereby preventing RAC1 inactivation and sustaining RAC1-GTP levels that drive mesenchymal invasion, migration, and cancer cell stemness[37][39]. RASAL2 knockdown in multiple TNBC cell lines reduces invasiveness, migration, mammosphere formation, and CD44+CD24lo cancer stem cell populations without affecting cell proliferation in monolayer culture, suggesting selective effects on invasion and stemness rather than proliferation[37][39]. In vivo tail-vein injection metastasis studies using TNBC cells demonstrate that RASAL2 overexpression dramatically enhances lung metastasis while RASAL2 knockdown suppresses metastatic colonization, establishing RASAL2 as a pro-metastatic factor in the TNBC context[37][39]. The mechanism by which RASAL2 activates RAC1 through antagonization of ARHGAP24 appears to involve direct binding interactions that block ARHGAP24's GAP activity, effectively shifting the RAC1 GTP/GDP equilibrium toward the active GTP-bound state and sustaining pro-invasive RAC1 signaling[37][39].

This context-dependent dichotomy of RASAL2 function, wherein it acts as a tumor suppressor in luminal B cancers through Ras inhibition while simultaneously acting as an oncogenic driver in triple-negative cancers through RAC1 activation, highlights the importance of cellular context in determining protein function and underscores the complexity of using RASAL2 as a potential therapeutic target without careful consideration of cancer subtype[37][39][43]. The differential phosphorylation states of RASAL2 in estrogen receptor-positive versus estrogen receptor-negative cells, with phosphorylated RASAL2 expression being significantly lower in ER+ cells despite higher total RASAL2 expression, suggests that post-translational modification patterns may contribute to these context-dependent functional differences[8][36][39].

Autophagy Regulation and Metabolic Stress Responses

Beyond its well-characterized roles in Ras pathway regulation and cancer suppression, RASAL2 functions as a critical regulator of autophagy, a cellular degradation pathway essential for survival under nutrient stress and conditions of energy depletion[38][45][48]. Under nutrient-rich conditions, unphosphorylated RASAL2 suppresses basal autophagy by recruiting the phosphatase PPM1B to dephosphorylate and inactivate AMPK, thereby preventing AMPK-dependent initiation of autophagosome formation and allowing cells to maintain anabolic processes under favorable metabolic conditions[38][45][48]. Upon glucose deprivation and metabolic stress, RASAL2 undergoes phosphorylation at serine 351 by activated AMPK, leading to dissociation of PPM1B and transition of RASAL2 to a positive regulator of autophagy through binding with the PIK3C3/VPS34-ATG14-BECN1/Beclin1 autophagy initiation complex, thereby promoting autophagosome formation and cell survival under nutrient stress[38][45][48]. This remarkable functional switch, achieved through phosphorylation at a single serine residue, converts RASAL2 from a suppressor to a promoter of autophagy depending on metabolic state, representing an elegant example of how post-translational modifications enable proteins to function as metabolic sensors.

The mechanism by which phosphorylated RASAL2 enhances autophagy involves increased activity of the PIK3C3 complex toward its substrate phosphatidylinositol (PtdIns), as evidenced by enhanced binding of phosphorylated RASAL2 to PIK3C3 complex components and increased phosphoinositide production by PIK3C3[45]. RASAL2's inhibition of basal autophagy through PPM1B-mediated AMPK dephosphorylation operates independently of its RAS-GAP catalytic activity, as RASAL2 RAS-GAP catalytic domain mutants retain full ability to suppress autophagy, while GAP domain-deleted constructs lose this function, indicating that RASAL2 requires GAP domain structure but not its enzymatic activity toward Ras for autophagy regulation[38][45][48]. These findings establish RASAL2 as a multifunctional protein whose roles extend well beyond Ras-MAPK pathway regulation to encompass critical metabolic checkpoints governing cell survival under stress.

Protein-Protein Interactions and Family Member Cooperation

RASAL2 belongs to the RAS-GAP family of proteins, sharing structural and functional similarities with RASA1, RASA2, RASA3, and other family members while exhibiting distinct regulatory mechanisms and tissue distributions[1][12][29][46]. RASA1, the prototypical RasGAP also known as p120GAP, shares with RASAL2 the characteristic RasGAP domain architecture and dual substrate specificity for Ras and Rap, though the two proteins differ in their membrane-targeting mechanisms, with RASA1 containing SH2/SH3 domains while RASAL2 contains PH and C2 domains[12][29][46]. RASAL2 cooperates with another RasGAP family member, DAB2IP (Disabled-2 Interacting Protein), to limit metastasis in estrogen receptor-positive breast cancer, with loss of either RASAL2 or DAB2IP alone promoting tumor growth, while simultaneous loss of both proteins dramatically increases invasion and metastasis, suggesting non-redundant suppressive functions of these two RasGAPs in preventing breast cancer dissemination[43]. The cooperative interaction between RASAL2 and DAB2IP appears to involve both shared Ras pathway inhibition and distinct non-catalytic functions, as demonstrated by studies showing that GAP-deficient DAB2IP mutants can reduce metastasis while remaining unable to suppress primary tumor growth, indicating mechanistic separability of tumor growth suppression from metastasis prevention[43].

RASAL2 interacts with other signaling proteins and adaptor molecules whose identities are being systematically characterized through mass spectrometry and yeast two-hybrid screens, with protein-protein interaction studies identifying associations with diverse signaling components whose functional significance remains to be fully elucidated[41]. The association of RASAL2 with ARHGAP24, discovered through investigations of RASAL2's oncogenic function in triple-negative breast cancer, represents a novel protein-protein interaction that appears functionally important for RAC1 activation in specific cellular contexts[37][39]. Whether RASAL2 serves as an adaptor protein that recruits other signaling molecules to specific membrane compartments, or whether it functions primarily through direct enzymatic activity on Ras and Rap substrates, remains an open question that future structural and biochemical studies should address.

Conclusions and Future Perspectives

RASAL2 emerges from the extensive scientific literature as a multifunctional regulator of Ras and Rap signaling that operates through multiple distinct mechanisms including direct GAP activity toward small GTPases, membrane-localized spatial organization through C2 and PH domain interactions with lipids, phosphorylation-dependent functional switching in response to metabolic stress and AMPK activation, and scaffolding functions through direct protein-protein interactions with other signaling molecules[3][7][8][9][12][14][25][26][31][37][38][39][45][48]. The structural basis for RASAL2's catalytic function involves a conserved C2 domain-mediated interaction with the Ras allosteric lobe that augments the catalytic efficiency of the adjacent GAP domain, a mechanism conserved across nine of ten mammalian RasGAPs and representing a fundamental architectural principle underlying RasGAP function[3][14][58]. The calcium and lipid-responsive C2 domains enable spatial recruitment of RASAL2 to the plasma membrane where both RASAL2 and its Ras substrates concentrate, providing a regulatory mechanism that links intracellular calcium signaling to Ras pathway inhibition[25][26][51].

The context-dependent dichotomy of RASAL2 function—functioning as a tumor suppressor in luminal B breast cancers through Ras inhibition while simultaneously promoting metastasis in triple-negative cancers through RAC1 activation—underscores the fundamental importance of cellular context, protein phosphorylation patterns, and cell type-specific signaling networks in determining the net biological outcome of a given protein's expression and activity. Future investigations should focus on elucidating the structural bases for substrate specificity switching between Ras and Rap, characterizing the complete set of RASAL2 protein-protein interactions and their functional consequences, determining how phosphorylation patterns regulate context-dependent switching between tumor suppressive and pro-tumorigenic functions, and exploring the therapeutic potential of modulating RASAL2 activity in different cancer subtypes where its roles diverge. The discovery that RASAL2 functions as a metabolic sensor through AMPK-dependent phosphorylation that switches autophagy regulation opens new avenues for investigating RASAL2's roles in cellular stress responses and potential connections between metabolic dysfunction and cancer development in RASAL2-dysregulated tumors.

[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][18][20][22][25][26][29][30][31][32][33][36][37][38][39][40][41][42][43][45][46][48][51][58]

Citations

1. https://www.ncbi.nlm.nih.gov/gene/9462
2. https://www.proteinatlas.org/ENSG00000075391-RASAL2
3. https://pmc.ncbi.nlm.nih.gov/articles/PMC11831179/
4. https://www.uniprot.org/uniprotkb/Q9UJF2/entry
5. https://geneglobe.qiagen.com/us/knowledge/gene/ENSG00000075391
6. https://www.uniprot.org/uniprotkb/E9PW37/entry
7. https://pmc.ncbi.nlm.nih.gov/articles/PMC3822334/
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC6921363/
9. https://www.nature.com/articles/cddis20179
10. https://www.nature.com/articles/s41598-025-16325-6
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC6396337/
12. https://www.proteinatlas.org/ENSG00000075391-RASAL2/tissue
13. https://pmc.ncbi.nlm.nih.gov/articles/PMC129411/
14. https://www.proteinatlas.org/ENSG00000075391-RASAL2/brain
15. https://dash.harvard.edu/bitstreams/efd25146-c25e-485f-adcb-baa98d8c9d9a/download
16. https://pubmed.ncbi.nlm.nih.gov/33563064/
17. https://pmc.ncbi.nlm.nih.gov/articles/PMC5546037/
18. https://pmc.ncbi.nlm.nih.gov/articles/PMC2670103/
19. https://pmc.ncbi.nlm.nih.gov/articles/PMC140691/
20. https://www.tandfonline.com/doi/full/10.4161/sgtp.2.1.15113
21. https://pubmed.ncbi.nlm.nih.gov/12529399/
22. https://www.pnas.org/doi/10.1073/pnas.1201658110
23. https://pmc.ncbi.nlm.nih.gov/articles/PMC3538246/
24. https://pmc.ncbi.nlm.nih.gov/articles/PMC6602148/
25. https://pmc.ncbi.nlm.nih.gov/articles/PMC6497929/
26. https://www.genecards.org/cgi-bin/carddisp.pl?gene=RASAL2
27. https://pmc.ncbi.nlm.nih.gov/articles/PMC4196159/
28. https://www.jci.org/articles/view/76711
29. https://pmc.ncbi.nlm.nih.gov/articles/PMC8632340/
30. https://pmc.ncbi.nlm.nih.gov/articles/PMC6940604/
31. https://www.spandidos-publications.com/10.3892/ol.2017.5581
32. https://www.proteinatlas.org/ENSG00000075391-RASAL2/interaction
33. https://www.oncotarget.com/article/2244/text/
34. https://www.nature.com/articles/s41418-024-01332-3
35. https://www.nature.com/articles/372786a0
36. https://pmc.ncbi.nlm.nih.gov/articles/PMC7610306/
37. https://pmc.ncbi.nlm.nih.gov/articles/PMC3141262/
38. http://biogps.org/gene/9462/
39. https://pubmed.ncbi.nlm.nih.gov/23251034/
40. http://next.monarchinitiative.org/MGI:2443881
41. https://www.uniprot.org/uniprotkb/D4AAY3
42. https://pmc.ncbi.nlm.nih.gov/articles/PMC8433508/
43. https://link.aps.org/doi/10.1103/PRXLife.3.023009
44. https://pmc.ncbi.nlm.nih.gov/articles/PMC1855010/
45. https://www.pnas.org/doi/10.1073/pnas.89.8.3649
46. https://pmc.ncbi.nlm.nih.gov/articles/PMC8608402/